Literature DB >> 20063196

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.

Javier Puente1, Sara López-Tarruella, Amparo Ruiz, Ana Lluch, Miguel Pastor, Emilio Alba, Juan de la Haba, Manuel Ramos, Luis Cirera, Antonio Antón, Antoni Llombart, Arrate Plazaola, Antonio Fernández-Aramburo, Javier Sastre, Eduardo Díaz-Rubio, Miguel Martin.   

Abstract

Women with recurrent metastatic breast cancer from a Spanish hospital registry (El Alamo, GEICAM) were analyzed in order to identify the most helpful prognostic factors to predict survival and to ultimately construct a practical prognostic index. The inclusion criteria covered women patients diagnosed with operable invasive breast cancer who had metastatic recurrence between 1990 and 1997 in GEICAM hospitals. Patients with stage IV breast cancer at initial diagnosis or with isolated loco-regional recurrence were excluded from this analysis. Data from 2,322 patients with recurrent breast cancer after primary treatment (surgery, radiation and systemic adjuvant treatment) were used to construct the prognostic index. The prognostic index score for each individual patient was calculated by totalling up the scores of each independent variable. The maximum score obtainable was 26.1. Nine-hundred and sixty-two patients who had complete data for all the variables were used in the computation of the prognostic index score. We were able to stratify them into three prognostic groups based on the prognostic index score: 322 patients in the good risk group (score < or =13.5), 308 patients in the intermediate risk group (score 13.51-15.60) and 332 patients in the poor risk group (score > or =15.61). The median survivals for these groups were 3.69, 2.27 and 1.02 years, respectively (P < 0.0001). In conclusion, risk scores are extraordinarily valuable tools, highly recommendable in the clinical practice.

Entities:  

Mesh:

Year:  2010        PMID: 20063196     DOI: 10.1007/s10549-009-0687-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.

Authors:  Antonio Giordano; Brian L Egleston; David Hajage; Joseph Bland; Gabriel N Hortobagyi; James M Reuben; Jean-Yves Pierga; Massimo Cristofanilli; Francois-Clement Bidard
Journal:  Clin Cancer Res       Date:  2013-01-22       Impact factor: 12.531

2.  Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.

Authors:  Lanell M Peterson; Janet O'Sullivan; Qian Vicky Wu; Alena Novakova-Jiresova; Isaac Jenkins; Jean H Lee; Andrew Shields; Susan Montgomery; Hannah M Linden; Julie Gralow; Vijayakrishna K Gadi; Mark Muzi; Paul Kinahan; David Mankoff; Jennifer M Specht
Journal:  J Nucl Med       Date:  2018-05-10       Impact factor: 10.057

3.  Defining the survival benchmark for breast cancer patients with systemic relapse.

Authors:  Simon B Zeichner; Tadeu Ambros; John Zaravinos; Alberto J Montero; Reshma L Mahtani; Eugene R Ahn; Aruna Mani; Nathan J Markward; Charles L Vogel
Journal:  Breast Cancer (Auckl)       Date:  2015-04-15

4.  Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

Authors:  D J A Lobbezoo; R J W van Kampen; A C Voogd; M W Dercksen; F van den Berkmortel; T J Smilde; A J van de Wouw; F P J Peters; J M G H van Riel; N A J B Peters; M de Boer; P G M Peer; V C G Tjan-Heijnen
Journal:  Br J Cancer       Date:  2015-04-16       Impact factor: 7.640

5.  Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients.

Authors:  Haeyoung Kim; Doo Ho Choi; Won Park; Seung Jae Huh; Seok Jin Nam; Jeong Eon Lee; Jin Seok Ahn; Young-Hyuck Im
Journal:  Radiat Oncol J       Date:  2013-12-31

6.  Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.

Authors:  Peggy L Lin; Yanni Hao; Jipan Xie; Nanxin Li; Yichen Zhong; Zhou Zhou; James E Signorovitch; Eric Q Wu
Journal:  Cancer Med       Date:  2015-12-21       Impact factor: 4.452

Review 7.  A Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast Cancer.

Authors:  Daniel M Sciubba; C Rory Goodwin; Alp Yurter; Derek Ju; Ziya L Gokaslan; Charles Fisher; Laurence D Rhines; Michael G Fehlings; Daryl R Fourney; Ehud Mendel; Ilya Laufer; Chetan Bettegowda; Shreyaskumar R Patel; Y Raja Rampersaud; Arjun Sahgal; Jeremy Reynolds; Dean Chou; Michael H Weber; Michelle J Clarke
Journal:  Global Spine J       Date:  2015-10-21

8.  Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.

Authors:  Sophie Frank; Matthieu Carton; Coraline Dubot; Mario Campone; Barbara Pistilli; Florence Dalenc; Audrey Mailliez; Christelle Levy; Véronique D'Hondt; Marc Debled; Thomas Vermeulin; Bruno Coudert; Christophe Perrin; Anthony Gonçalves; Lionel Uwer; Jean-Marc Ferrero; Jean-Christophe Eymard; Thierry Petit; Marie-Ange Mouret-Reynier; Anne Patsouris; Tahar Guesmia; Thomas Bachelot; Mathieu Robain; Paul Cottu
Journal:  Breast       Date:  2020-04-23       Impact factor: 4.380

Review 9.  Computational prognostic indicators for breast cancer.

Authors:  Xinan Yang; Xindi Ai; John M Cunningham
Journal:  Cancer Manag Res       Date:  2014-07-12       Impact factor: 3.989

10.  Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.

Authors:  Gladys Morrison; Divya Lenkala; Bonnie LaCroix; Dana Ziliak; Vandana Abramson; Phuong Khanh Morrow; Andres Forero; Catherine Van Poznak; Hope S Rugo; Rita Nanda; Peter H O'Donnell; R Stephanie Huang
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.